Clean Science and Technology Limited announces the commencement of commercial production of Hydroquinone (HQ) and Catechol. This milestone was achieved by their wholly-owned subsidiary, Clean Fino-Chem Limited (CFCL), on Thursday, December 18, 2025. The company anticipates this will reduce import dependency and enhance their market position, particularly with MEHQ customers, and will lead to captive use for Guaiacol and Veratrole production.
Hydroquinone and Catechol Production
Clean Science and Technology Limited has started commercial production of Hydroquinone (HQ) and Catechol. This was announced on December 18, 2025, through their wholly-owned subsidiary, Clean Fino-Chem Limited (“CFCL”). This move marks a significant step in strengthening the company’s specialty chemical portfolio.
Key Benefits
The commencement of production is expected to bring several key benefits:
- The Company is expected to become a key domestic manufacturer of Hydroquinone and Catechol, reducing reliance on imports.
- Commercialization of Hydroquinone is expected to strengthen the value proposition of performance segment. It creates cross-selling opportunities with MEHQ customers and supports the enhancement of TBHQ market share.
- Catechol produced will be used internally for production of Guaiacol and Veratrole.
R&D Capabilities
The commercialization of Hydroquinone and Catechol underscores Clean Science’s R&D capabilities and in-house project engineering capabilities, emphasizing the company’s focus on specialty chemicals.
Source: BSE